Charlotte's Web Holdings, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Charlotte’s Web performed. My goal is to explain their filings in simple terms so you can decide if this company fits your investment goals.

1. What does this company do?

Charlotte’s Web is a leader in the hemp-based CBD industry. They sell premium oils, gummies, and skin creams, and have recently added functional mushrooms and low-dose THC products to their lineup. As a "Public Benefit Company," they are legally required to balance profits with social and environmental goals. Most of their sales—about 60% to 65%—come directly from their website. The rest comes from selling their products in roughly 15,000 retail stores nationwide.

2. Financial performance

The company is currently in survival mode, working to stabilize its finances after losing about $37.5 million last year. They do not pay dividends, so you only profit if the stock price increases. To save cash, they ended an $18 million marketing deal with Major League Baseball. They also hired a new accounting firm to fix past errors and improve how they report their financial data.

3. Major wins and changes

• The "BAT" Lifeline: British American Tobacco (BAT) is becoming the company's main financial backer. In early 2026, they agreed to swap their debt for company stock and invest an extra $10 million. This removes expensive interest payments. However, the company will issue 110 million new shares. This means your ownership percentage will shrink, and BAT will gain majority control.
• Product Innovation: They are moving beyond basic CBD to sell higher-profit wellness items. New products include mushroom gummies and "Brightside" THC gummies. These use special technology to help your body absorb the product faster, helping them stand out from cheaper competitors.
• Leadership Shuffle: The company replaced its top management to fix past inefficiencies. New CEO Bill Morachnick and CFO Erika Lind are now leading a plan to cut costs and push the company toward profit.

4. Financial health

The company is in a tight spot. They have less than $10 million in cash left and are spending $2 million to $4 million more than they make each quarter. They are trying to bring production in-house to keep more profit from each sale, but they still need outside funding to survive. Their future depends entirely on the BAT deal, which shareholders must vote on in May 2026.

5. Key risks

• Dilution: The BAT deal saves the company from running out of money, but it comes at a cost. Issuing 110 million new shares means your slice of the company gets much smaller.
• Regulatory Uncertainty: The government still lacks clear rules for CBD. States like California are trying to restrict hemp sales, which threatens the company’s ability to sell in its biggest markets.
• Legal & Operational Costs: Lawsuits and patent fees continue to drain cash. Additionally, staying listed on stock exchanges in both Canada and the U.S. creates high legal and administrative costs.

6. Future outlook

Management is betting everything on the BAT partnership and new products to move beyond basic CBD. They want to become a broader wellness brand using BAT’s expertise. If the 2026 deal passes, the company will have much less debt. However, investors should be aware that one partner will soon hold most of the control.

Final Thought for Investors: When considering this stock, ask yourself if you believe in the turnaround plan led by the new management team. The upcoming shareholder vote on the BAT deal is the most important event on the horizon; it will determine whether the company gains the stability it needs to grow or remains under extreme financial pressure. Always weigh the potential for a brand pivot against the reality of significant share dilution.